While PGRN’s role as an AD biomarker remains uncertain, its increased CSF levels during disease progression, correlation with cognitive decline and neurodegeneration markers, and involvement in protein aggregation and neuroinflammation suggest that it could be a key player in AD by modulating microglial response and Aβ/tau clearance. The gene discussed is MAPT; the disease is Mental deterioration.